223 related articles for article (PubMed ID: 6285799)
1. Histological types of nasopharyngeal carcinoma as compared to EBV serology.
Krueger GR; Kottaridis SD; Wolf H; Ablashi DV; Sesterhenn K; Bertram G
Anticancer Res; 1981; 1(4):187-94. PubMed ID: 6285799
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
Liu MT; Yeh CY
Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
[TBL] [Abstract][Full Text] [Related]
3. [Immunoglobulin A serum antibodies against the capsid antigen of Epstein-Barr virus in the differential diagnosis and follow-up of nasopharyngeal cancer].
Pavelka R; Popow-Kraupp T; Radaszkiewicz T
Wien Klin Wochenschr; 1985 Jul; 97(14):588-95. PubMed ID: 2996246
[TBL] [Abstract][Full Text] [Related]
4. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L
J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480
[TBL] [Abstract][Full Text] [Related]
5. [Carcinomas of the nasopharynx. Relationship between histological type and anti-Epstein-Barr virus serology (author's transl)].
Micheau C; de The G; Orofiamma B; Schwaab G; Brugere J; Tursz T; Sancho-Garnier H; Cachin Y
Nouv Presse Med; 1980 Jan; 9(1):21-4. PubMed ID: 6243770
[TBL] [Abstract][Full Text] [Related]
6. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
7. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
Mazeron MC
Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
[TBL] [Abstract][Full Text] [Related]
8. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
[TBL] [Abstract][Full Text] [Related]
9. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
[TBL] [Abstract][Full Text] [Related]
10. [Significance of virus-specific antibodies to EBV-antigens in patients with nasopharyngeal carcinoma (author's transl)].
Wilmes E; Wolf H; Deinhardt F; Naumann HH
Laryngol Rhinol Otol (Stuttg); 1979 Dec; 58(12):911-5. PubMed ID: 231716
[TBL] [Abstract][Full Text] [Related]
11. Titers of Epstein-Barr virus-related antibodies in nasopharyngeal carcinoma in Japan.
Tamada A; Makimoto K; Yamabe H; Imai J; Hinuma Y; Oyagi A; Araki T
Cancer; 1984 Feb; 53(3):430-40. PubMed ID: 6318948
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
[TBL] [Abstract][Full Text] [Related]
13. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
Wilmes E; Wolf H; Deinhardt F; Naumann HH
Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
[TBL] [Abstract][Full Text] [Related]
14. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
[TBL] [Abstract][Full Text] [Related]
15. Serologic diagnosis of nasopharyngeal carcinoma. A double-blind study of four EB virus antibodies with evaluation by sequential discrimination.
Cai WM; Li YW; Wu B; Liu YY; Hu YH; Gu XZ; Liu HY; Wang GD
Int J Radiat Oncol Biol Phys; 1983 Dec; 9(12):1763-8. PubMed ID: 6319338
[TBL] [Abstract][Full Text] [Related]
16. Epstein Barr virus (EBV) antibodies in the diagnosis of NPC--comparison between IFA and two commercial ELISA kits.
Chan SH; Soo MY; Gan YY; Fones-Tan A; Sim PS; Kaur A; Chew CT
Singapore Med J; 1998 Jun; 39(6):263-5. PubMed ID: 9803815
[TBL] [Abstract][Full Text] [Related]
17. A prospective evaluation of patients with nasopharyngeal carcinoma: an overview.
Neel HB
J Otolaryngol; 1986 Jun; 15(3):137-44. PubMed ID: 3014165
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland.
Friborg J; Jarrett RF; Liu MY; Falk KI; Koch A; Olsen OR; Duncan P; Wohlfarht J; Chen JY; Melbye M
J Med Virol; 2007 Dec; 79(12):1877-81. PubMed ID: 17935169
[TBL] [Abstract][Full Text] [Related]
19. Nasopharyngeal carcinoma: Epstein-Barr Virus significance.
Kottaridis SD; Panotopoulou E; Diamantis I; Goula I; Danilidis J; Fountzilas G
Anticancer Res; 1996; 16(2):785-9. PubMed ID: 8687129
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review.
Tsang RK; Vlantis AC; Ho RW; Tam JS; To KF; van Hasselt CA
Head Neck; 2004 Jul; 26(7):598-602. PubMed ID: 15229902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]